Galapagos NV initiated with an Overweight at Cantor Fitzgerald. Cantor Fitzgerald analyst Eliana Merle started Galapagos NV with an Overweight rating and $130 price target. 2019 will be the year that filgotinib could differentiate itself among the JAK inhibitors, Merle tells investors in a research note. The analyst thinks filgotinib’s potential is underappreciated and that upside could come from Phase 3 readouts that will show its profile.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.